+357 96 030922
info@marketpublishers.com

Pancreatic Cancer Diagnostic Market By Product (Instruments, Consumables), By Test Type (Imaging Test, Blood Test, Biopsy), By Cancer Type (Exocrine, Endocrine), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035

https://marketpublishers.com/r/P16AE735A872EN.html
Date: March 2025
Pages: 368
Price: US$ 2,655.00 (Single User License)
ID: P16AE735A872EN

Abstracts

The pancreatic cancer diagnostic market was valued at $1.6billion in 2023 and is estimated to reach $3.2billion by 2035, exhibiting a CAGR of 5.9% from 2024 to 2035. Pancreatic cancer diagnostics involves the identification and confirmation of pancreatic cancer through various medical techniques and tools. This process typically begins with a detailed review of the patient’s medical history and symptoms, followed by physical examinations and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic ultrasound (EUS). These imaging modalities help visualize abnormalities in the pancreas and surrounding tissues. In addition, blood tests may be conducted to detect biomarkers such as CA 19-9, a protein often elevated in pancreatic cancer patients. Biopsies obtained through fine-needle aspiration or surgical procedures provide a definitive diagnosis by allowing microscopic examination of pancreatic tissue for cancerous cells. Early and accurate diagnosis is critical for guiding treatment decisions and improving patient outcomes.

The pancreatic cancer diagnostic market is driven by increase in prevalence of pancreatic cancer, advancements in diagnostic technologies, rise in awareness about early detection, and rise in demand for non-invasive diagnostic techniques. Pancreatic cancer, known for its aggressive nature and poor prognosis, is one of the leading causes of cancer-related deaths globally. Rise in incidence of pancreatic cancer, coupled with lack of effective early diagnostic methods, has created a significant need

for innovative diagnostic solutions. In addition, rise in technological advancements in imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS), have enhanced the ability to detect pancreatic tumors at earlier stages, thereby supporting the market growth. These imaging modalities offer high-resolution images that enable clinicians to identify pancreatic abnormalities with greater accuracy. The advent of more advanced tools, such as molecular imaging and liquid biopsy, is also contributing to the market growth by allowing for earlier detection and improved patient monitoring.

Furthermore, traditional diagnostic methods such as surgical biopsies are often associated with higher risks and recovery times, leading to a shift toward non-invasive techniques like blood tests, urine tests, and liquid biopsy, which drives the market growth. Liquid biopsy, which analyzes blood or other bodily fluids for cancer-related biomarkers, is emerging as a promising tool for diagnosing pancreatic cancer, as it reduces the need for more invasive procedures while providing valuable molecular insights.

Rise in awareness of pancreatic cancer and the importance of early detection is also fueling the market growth. Awareness campaigns, along with better access to healthcare services, have contributed to rise in screening and diagnostic procedures. Governments, healthcare organizations, and advocacy groups are focusing on educating the public about signs and symptoms of pancreatic cancer, emphasizing the significance of early diagnosis in improving survival rates.

However, high cost of advanced diagnostic technologies, such as molecular testing and imaging techniques, can limit accessibility, particularly in low-income regions. In addition, lack of specialized healthcare infrastructure and trained medical professionals in certain areas hinders the effective implementation and use of these diagnostic tools. On the other hand, rise in focus of government and healthcare organizations on early cancer detection creates a favorable environment for the adoption of advanced diagnostic tools. Expanding healthcare infrastructure in emerging markets, particularly in LAMEA, opens up new avenues for introducing cutting-edge diagnostic technologies.

The pancreatic cancer diagnostic market is segmented into product, test type, cancer type, end user, and region. By product, the market is segregated into instruments and consumables. By test type, the market is categorized into imaging test, blood test, and biopsy. By cancer type, the market is classified into exocrine and endocrine. The exocrine segment is further categorized into adenocarcinoma, adenosquamous carcinoma, colloid carcinoma, and others. By end user, the market is classified into hospitals and clinics, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major players that operate in the pancreatic cancer diagnostic market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Randox Laboratories Ltd., Prestige Biopharma Ltd., Siemens, ClearNote Health, Qiagen N.V., Toray Industries, Inc., and Myriad Genetics, Inc. Key players have adopted product launch, agreement, collaboration, and product approval as key developmental strategies to improve the product portfolio of the pancreatic cancer diagnostic market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pancreatic cancer diagnostic market analysis from 2023 to 2035 to identify the prevailing pancreatic cancer diagnostic market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pancreatic cancer diagnostic market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pancreatic cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.

+357 96 030922
info@marketpublishers.com

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Average Selling Price Analysis / Price Point Analysis

Expanded list for Company Profiles

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Volume Market Size and Forecast

Key Market Segments

By Product

Instruments

Consumables

Type

kits

Needles

Others

By Test Type

Blood Test

Biopsy

Imaging Test

By Cancer Type

Exocrine

Type

Adenocarcinoma

Adenosquamous Carcinoma

Others

Endocrine

By End User

Hospitals

Diagnostic Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

+357 96 030922
info@marketpublishers.com

- Spain
- Rest of Europe

Asia-Pacific

- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

LAMEA

- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players

- F. Hoffmann-La Roche Ltd.
- Fujifilm Holdings Corporation
- Prestige Biopharma Ltd.
- Siemens

+357 96 030922
info@marketpublishers.com

ClearNote Health

Toray Industries, Inc.

Myriad Genetics, Inc.

Thermo Fisher Scientific Inc.

Randox Laboratories Ltd.

Qiagen N.V.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 7: PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER

CHAPTER 8: PANCREATIC CANCER DIAGNOSTIC MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Pancreatic Cancer Diagnostic Market By Product (Instruments, Consumables), By Test Type (Imaging Test, Blood Test, Biopsy), By Cancer Type (Exocrine, Endocrine), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035

Product link: https://marketpublishers.com/r/P16AE735A872EN.html

Price: US$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P16AE735A872EN.html